Analyst Price Target is $27.43
▲ +98.90% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Adicet Bio in the last 3 months. The average price target is $27.43, with a high forecast of $34.00 and a low forecast of $21.00. The average price target represents a 98.90% upside from the last price of $13.79.
Current Consensus is
The current consensus among 7 investment analysts is to buy stock in Adicet Bio.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.